ОСОБЕННОСТИ ТЕЧЕНИЯ ВИРУСНЫХ ГЕПАТИТОВ У ПАЦИЕНТОВ С ОНКОГЕМАТОЛОГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Частым осложнением химиотерапии пациентов с онкогематологическими заболеваниями является нарушение функции печени. Основными причинами, как правило, являются вирусы гепатитов В и С, цитомегаловирус и вирус простого герпеса. Вирусы гепатитов В и С могут вызывать тяжелые нарушения функции печени, в т. ч. молниеносный гепатит, реактивацию или нарастание репликации вируса. Вирусные гепатиты и их осложнения оказывают негативное влияние на течение основной патологии у онкогематологических больных, снижают эффективность противоопухолевой терапии, ухудшают прогноз, качество жизни и выживаемость, представляют угрозу здоровью выздоровевших пациентов из-за риска формирования цирроза печени и гепатоцеллюлярной карциномы. Своевременные диагностика и лечение вирусных гепатитов крайне необходимы для сведения к минимуму смертности от этих заболеваний.

Полный текст

Доступ закрыт

Об авторах

Р. И Вабищевич

Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова, Санкт-Петербург

Ю. А Алексеева

Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова, Санкт-Петербург

к.м.н.

Список литературы

  1. Nordbo S.A., Skaug K, Holter E., Waage A., Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 2000;65:86-7.
  2. Steinberg J.L., Yeo W., Zhong S., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000;60:249-55.
  3. Xunrong L., Yan A.W., Liang R., Lau G.K. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001;11:287-99.
  4. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
  5. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
  6. Zekri A.R., Mohamed W.S., Samra M.A., et al. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004;13:305-11.
  7. Knoll A., Boehm S., Hahn J., Holler E., Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:925-29.
  8. Kumagai K., Takagi T., Nakamura S., et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107-9.
  9. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. Lavanchi D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Virol Hepat 2004;11:97-107.
  10. Yim H.J., Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81.
  11. Blackberg J., Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-97.
  12. Firpi R.J., Martin P. Update on hepatitis B treatment. Med Gen Med 2002;4:9.
  13. de Franchis R., Hadengue A., Lau G., et al. EASL International Consensus Conference on Hepatitis B. 13-4 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-25.
  14. Kitano K., Kobayashi H., Hanamura M., et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006;77:255-58.
  15. Lubel J.S., Testro A.G., Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705-12.
  16. Hui C.K., Cheung W.W., Zhang H.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131:59-68.
  17. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 2007;136:699-712.
  18. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182-88.
  19. Zhong S., Yeo W., Schroder S, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004;11:55-9.
  20. Hui C.K., Lie A., Au W.Y. et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005;106:464-69.
  21. Maguire C.M., Crawford D.H., Hourigan L.F., et al. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol 1999;14:801-3.
  22. Markovic S., Drozina G., Vovk M., Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925-30.
  23. Silvestri F., Sperotto A., Ermacora A., et al. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica 2000;85:327-29.
  24. Ustun C., Koc H., Karayalcin S., et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20:289-96.
  25. Wong G.C., Tan P., Goh Y.T., et al. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 1996;25:500-03.
  26. Yagci M., Sucak G.T., Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. Am J Hematol 2000;64:233-34.
  27. Yeo W., Steinberg J.L., Tam J.S., et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263-69.
  28. Lau G.K., He M.L., Fong D.Y., et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-09.
  29. Martyak L.A., Taqavi E., Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28(1):28-38.
  30. Yeo W., Chan P.K., Ho W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-34.
  31. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007;45:507-39.
  32. Leung N.W., Tam J.S., Lau G.T., et al. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994;73:1143-48.
  33. Onozawa M., Hashino S., Izumiyama K., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplanta -tion in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-19.
  34. Senecal D., Pichon E., Dubois F., et al. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 1999;24:1243-44.
  35. Dreger P., Rautenberg P., Kneba M., Schmitz N. Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC. Bone Marrow Transplant 2000;26:114-16.
  36. Iwai K., Tashima M., Itoh M., et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000; 25:105-8.
  37. Dhedin N., Douvin C., Kuentz M., et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616-19.
  38. Sekine R., Taketazu F., Kuroki M., et al. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int J Hematol 2000;71:256-58.
  39. McIvor C., Morton J., Bryant A., et al. Fatal reactivation of precore mutant hepatitis B virus associ ated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 1994; 121:274-75.
  40. Dai M.S., Wu P.F., Shyu R.Y., Lu J.J., Chao T.Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-46.
  41. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005;55:828-31.
  42. Jang J.W., Choi J.Y., Bae S.H., et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-40.
  43. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-49.
  44. Li Y.H., He Y.F., Jiang W.Q., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106:1320-25.
  45. Yeo W., Ho W.M., Hui P., et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209-15.
  46. Saab S., Dong M.H., Joseph T.A., Tong M.J. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007;46:1049-56.
  47. Hsiao L.T., Chiou T.J., Liu J.H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12:84-94.
  48. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
  49. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125: 1714-22.
  50. Perez-Roldan F., Gonzalez-Carro P., Villafanez-Garcia M.C. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 2005;352:310-11.
  51. Cortelezzi A., Vigano M., Zilioli V.R., et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006;35:467-69.
  52. Fouillard L., Serfaty L., Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:625-26.
  53. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209.
  54. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
  55. Davis G.L. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004;4:7-17.
  56. Locasciulli A., Testa M., Valsecchi M.G., et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999;68:1486-91.
  57. Peffault de Latour R., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103:1618-24.
  58. Ivantes C.A., Amarante H., Ioshii S.O., Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004;33:1181-85.
  59. Strasser S., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999;29:1893-99.
  60. Strasser S.I., Sullivan K.M., Myerson D., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999;93:3259-66.
  61. Zuckerman E., Zuckerman T., Douer D., Qian D., Levine A.M. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998;83:1224-30.
  62. Ribas A., Gale R.P. Should people with hepatitis C virus infection receive a bone marrow transplant? Bone Marrow Transplant 1997;19:97-9.
  63. Frickhofen N., Wiesneth M., Jainta C., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83:1998-2004.
  64. Gigliotti A.R., Fioredda F., Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003;25:184-92.
  65. Ho V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008 Feb;41:229-37.
  66. Peffault de Latour R., Levy V., Asselah T., et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005;36:709-13.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2013